Lifestyle Intervention in Patients With Metastatic Prostate Cancer

Korábbi kezelés

• Ongoing treatment with docetaxel, cabazitaxel, radionuclides or investigational treatments
• Prior confirmed severe osteoporosis or other diseases affecting the bone with history of fractures
• Clinically significant cardiovascular disease (i.e. myocardial infarction within 6 months before screening; uncontrolled angina within 3 months before screening; congestive heart failure New York Heart Association class 3 or 4; history of clinically significant arrhythmias; uncontrolled hypertension indicated by systolic blood pressure > 170 mm Hg or diastolic blood pressure > 105 mm Hg at screening)
• Any concurrent disease or comorbid condition that interferes with the ability of the patient to participate in the study

Más betegség

• Evidence of clinical progression or progression of disease on imaging
• Clinically significant chronic obstructive pulmonary disease

Egyéb

• Bone metastases excluding the safety of physical exercise

• Written informed consent according to ICH/GCP regulations before registration.
• Age ≥ 18 years
• Histology of adenocarcinoma of the prostate
• Patients with PCa receiving ADT alone or ADT+NHT (abiraterone, enzalutamide, apalutamide or darolutamide)
• Rising PSA (two consecutively rising PSA levels > 25% above nadir at least three weeks apart), with no evidence of clinical or radiographic progression on instrumental evaluation
• PSA doubling time > 8 weeks
• Continuation of ongoing systemic treatment is deemed feasible by treating physician